Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Diabetes Treatment
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 260367
The proprietary transdermal drug delivery technology is known as transdermal microprojection patch technology for use with GLP-1 Receptor Agonist(s).
GLP-1 Receptor Agonist(s) means any substance that binds to the GLP-1 receptor in vitro and activates it, as measured by initiation of an increase in cAMP, with at least 10 fold higher potency than native glucagon. For the avoidance of doubt, native glucagon is not a GLP-1 receptor agonist according to this definition.
IPSCIO Record ID: 383600
Licensed Products means any pharmaceutical formulation suitable for administration to humans where such formulation contains at least one Product in combination with a Program Carrier.
GLP-1 Receptor Agonist means a compound that has the ability to bind the GLP-1 receptor in vitro and initiate an increase in cAMP where such compounds include but are not limited to GLP-1 and GLP-1 analogs and derivatives and Exendin-4 and Exendin-4 analogs and derivatives but excluding Native GLP-1.
Native GLP-1 means GLP-1(7-36) amide and GLP-1 (7-37).
Products means any GLP-1 Receptor Agonists.
Program Carriers means up to 6 Carriers that are selected by Licensee, at its sole discretion, in writing during or before the Term of this Agreement from the Carriers made available by Licensee. Program Carriers may be either Exclusive Program Carriers or Non-Exclusive Program Carriers. Carrier 1082 and SNAC have been selected by License as an Exclusive Program Carrier and a Non-Exclusive Program Carrier respectively as of the Effective Date. Carrier 1082 and SNAC are sodium salts.
IPSCIO Record ID: 260368
— an exclusive license, even as to Licensor, under the Licensed Patents to make, have made, import, use, sell, offer for sale and have sold Products in the Field in the Territory, subject to rights already granted to a Third Party under the Development Agreement between Licensor and and the Third Party; and,
— a non-exclusive royalty-free license under the Future Licensor Patents to make, have made, import, use, sell, offer for sale and have sold Products in the Field in the Territory.
Licensor will assign to Licensee the Trademarks.
The Trademark means the trademark applications and registrations for the mark MACROFLUX.
Microprojection System means a microprojection array having a plurality of microprojections which pierce at least through the outmost layer, i.e., the stratum comeum layer, of the skin.
MacrofluxÂ® transdermal microprojection delivery system provides unique benefits including convenient needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines.
skin patch technology provides rapid and reproducible intracutaneous administration of dry-coated antigen. The depth of skin penetration targets skin immune cells; the quantity of antigen delivered can be controlled by formulation, patch wearing time, and system size. This novel needle-free patch technology may ultimately have broad applications for a wide variety of therapeutic vaccines to improve efficacy and convenience of use.
IPSCIO Record ID: 340300
Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It works to raise the concentration of glucose and fatty acids in the bloodstream, and is considered to be the main catabolic hormone of the body. It is also used as a medication to treat a number of health conditions. GLP-1 and GLP-2 are identifiers. Glucagon binds to the glucagon receptor, a G protein-coupled receptor, located in the plasma membrane of the cell.
SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function.